Wire · opportunities
FDA panel votes to place popular peptide BPC-157 on compounding list
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 23 July 2026 · Fusion42 review
An FDA advisory panel voted 8-6 to place BPC-157, a widely used peptide, on the compounding list, which would allow pharmacies to compound it more broadly without FDA approval for each formulation.
This Wire brief sits within Fusion42's coverage of Digital Health, and 9 sources have reported it between 23 Jul 2026 and 28 Jul 2026.
◆ ◆ The Wire takeaway
If you sell peptides direct-to-consumer like Hims, you just got permission to bypass the usual approval gauntlet. Compounding list status means your pharmacy partners can now scale faster and cheaper than prescription-only routes.
◆ Coverage
9 sources · first reported 23 Jul 2026 · latest 28 Jul 2026
◆ Topics